Detorsertib - Suzhou Kintor Pharmaceuticals
Alternative Names: GT-0486Latest Information Update: 29 Sep 2025
At a glance
- Originator Suzhou Kintor Pharmaceuticals
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 29 Sep 2025 Detorsertib is still in phase-I trials for Solid tumours (Metastatic disease) in China (unspecified route) (Suzhou Kintor Pharmaceuticals, September 2025)
- 28 Sep 2025 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in China
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)